Department of Medical Microbiology, Shi-Gan International College of Science and Technology, Tribhuvan University, Shankha marg, Kathmandu, Nepal. and Department of Clinical Laboratory, Nepal Armed Police Force Hospital, Balambu, Kathmandu, Nepal.
Department of Clinical Laboratory, Nepal Armed Police Force Hospital, Balambu, Kathmandu, Nepal.
Kathmandu Univ Med J (KUMJ). 2022 Jul-Sep;20(79):316-322.
Background Severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) variants, which have emerged due to several mutations in spike protein, have a potential to escape immune protection provided by the first-generation vaccines, thereby resulting in breakthrough infections. Objective To identify the socio-demographic factors, clinical features, and outcomes in both vaccinated and unvaccinated hospitalized patients infected with SARS-CoV-2. Method Socio-demographic details, clinical features, and the outcomes among fully vaccinated (double for Covishield/AstraZeneca and BBIBP-CorV and single for Janssen), partially vaccinated, and unvaccinated hospitalized patients with coronavirus disease of 2019 (COVID-19) were collected and analyzed using SPSS version 17. Result Among the hospitalized COVID-19 patients (n=299), 175 (58.5%) patients received a single-dose, 82 (27.4%) double-dose, and 124 (41.5%) did not receive any dose of the COVID-19 vaccines. The risk of SARS-CoV-2 infection when compared between vaccinated and unvaccinated patients was found to be associated among professional degree holders (23.4% versus 9.7%) (p<0.05), professional workers (43.4% vs. 25.0%) (p<0.05), hospitalization to general ward (76.6% vs. 72.6%) (p<0.05), and presence of multiple symptoms (> or equel 3) (86.8% vs. 75.0%) (p>0.05) and comorbidities (> or equal 2) (15.5% vs. 13.7%) (p>0.05). Despite such approximate incidences, the risk of in-hospital mortality among the vaccinated patients was reduced (0.6% vs. 3.2%) (p>0.05), when compared to the unvaccinated patients. The risk of in-hospital mortality was associated with the older age and the presence of multiple comorbidities including bronchial asthma, diabetes, and hypertension. Conclusion Full or partial vaccination against the SARS-CoV-2 variants of concerns might be effective in preventing in-hospital mortality among COVID-19 patients.
由于刺突蛋白发生了多次突变,严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)变体具有逃避第一代疫苗提供的免疫保护的潜力,从而导致突破性感染。目的:确定已接种和未接种 SARS-CoV-2 的住院患者的社会人口统计学因素、临床特征和结局。方法:使用 SPSS 版本 17 收集并分析了完全接种(Covishield/AstraZeneca 和 BBIBP-CorV 双剂量, Janssen 单剂量)、部分接种和未接种的 2019 年冠状病毒病(COVID-19)住院患者的社会人口统计学详细信息、临床特征和结局。结果:在住院 COVID-19 患者(n=299)中,175 例(58.5%)患者接受了单剂,82 例(27.4%)患者接受了双剂,124 例(41.5%)未接受任何 COVID-19 疫苗接种。与未接种疫苗的患者相比,发现接种疫苗和未接种疫苗的患者之间感染 SARS-CoV-2 的风险与专业学位持有者(23.4%对 9.7%)(p<0.05)、专业人员(43.4%对 25.0%)(p<0.05)、住院至普通病房(76.6%对 72.6%)(p<0.05)和存在多种症状(>或等于 3 种)(86.8%对 75.0%)(p>0.05)和合并症(>或等于 2 种)(15.5%对 13.7%)(p>0.05)相关。尽管发病率相近,但与未接种疫苗的患者相比,接种疫苗的患者的住院死亡率风险降低(0.6%对 3.2%)(p>0.05)。住院死亡率与年龄较大和存在多种合并症(包括支气管哮喘、糖尿病和高血压)有关。结论:针对 SARS-CoV-2 变体的全面或部分疫苗接种可能有助于预防 COVID-19 患者的住院死亡率。